Kathryn Giusti is the founder and CEO of the Multiple Myeloma Research Foundation (MMRF) and the Multiple Myeloma Research Consortium. Together, the two organizations have developed innovative models that serve to break down barriers that slow multiple myeloma research and accelerate the development of next-generation treatments. Chief among these are an integrated clinical network of academic centers that conduct early-stage clinical trials, as well as a state-of-the-art tissue bank that provides a foundation for the organizations' pursuit of personalized medicine.
Prior to founding the MMRF, Ms. Giusti was a pharmaceutical executive at G.D. Searle & Co., and previously held positions at Merck & Co. and the Gillette Company. Ms. Giusti, a multiple myeloma patient, was named to the "2011 TIME 100" list of the world's most influential people- a recognition she received for the progress she has made in accelerating the way research and drug development are conducted. Ms. Giusti has also received the American Association for Cancer Research Centennial Medal for Distinguished Public Service, the Harvard Business School Alumni Achievement Award, and the Healthcare Businesswomen's Association's Woman of the Year Award.
Ms. Giusti currently serves on the Executive Management Committee of Stand Up to Cancer and the Harvard Business School Healthcare Initiative Advisory Board. Previous board service includes the President's National Cancer Advisory Board, the Board of Directors for IMS Health, and the Institute of Medicine's National Cancer Policy Board.
She received a BS in biological sciences, magna cum laude, from the University of Vermont and an MBA from HBS.